Cognitive Change Clinical Trial
Official title:
The Acute and Chronic Cognitive Effects of a Sage Extract: a Randomized, Placebo Controlled Study in Healthy Humans
Verified date | March 2020 |
Source | Northumbria University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Extracts of sage and polyphenols have separately been reported to interact with central nervous system (CNS) mechanisms relevant to cognitive performance but, to date, no trial has combined these interventions. The current study investigates the effects of this combined intervention in N=90 healthy males and females between 30-60 yrs, at 600 mg versus placebo, on cognition and mood over a 29 day period.
Status | Completed |
Enrollment | 94 |
Est. completion date | September 24, 2019 |
Est. primary completion date | September 24, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 30 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Participants must self-assess themselves as being in good health. - Aged 30 to 60 years at the time of giving consent - In daytime employment and/or higher education Exclusion Criteria: - Have any pre-existing medical condition/illness which will impact taking part in the study NOTE: the explicit exceptions to this are controlled (medicated) arthritis, asthma, hay fever, high cholesterol and reflux-related conditions. There may be other, unforeseen, exceptions and these will be considered on a case-by-case basis; i.e. participants may be allowed to progress to screening if they have a condition/illness which would not interact with the active treatments or impede performance. - Are currently taking prescription medications NOTE: the explicit exceptions to this are contraceptive and hormone replacement treatments for female participants where symptoms are stable and treatment will not change during the course of the study, those medications used in the treatment of arthritis, high cholesterol and reflux-related conditions; and those taken 'as needed' in the treatment of asthma and hay fever. As above, there may be other instances of medication use which, where no interaction with the active treatments is likely, participants may be able to progress to screening. - Have high blood pressure (systolic over 159 mm Hg or diastolic over 99 mm Hg) - Have a Body Mass Index (BMI) outside of the range 18.5-30 kg/m2 - Are pregnant, seeking to become pregnant or lactating - Have learning and/or behavioural difficulties such as dyslexia or ADHD - Have a visual impairment that cannot be corrected with glasses or contact lenses (including colour-blindness) - Smoker - excessive caffeine intake (>500 mg per day) - Have food intolerances/ sensitivities - Have taken antibiotics, prebiotics or probiotics (including drinks. Eg. Yakult or Actimel) within the past 8 weeks - Have any health condition that would prevent fulfillment of the study requirements (this includes non-diagnosed conditions for which no medication may be taken) - Are unable to complete all of the study assessments - Are currently participating in other clinical or nutrition intervention studies, or have in the past 4 weeks - Has been diagnosed with/ undergoing treatment for alcohol or drug abuse in the last 12 months - Have been diagnosed with/ undergoing treatment for a psychiatric disorder in the last 12 months - Suffers from frequent migraines that require medication (more than or equal to 1 per month) - Sleep disturbances (including night-shift work) and/ or are taking sleep aid medication - Any known active infections - Does not have a bank account (required for payment) - Are non-compliant with regards treatment consumption (see 4.3) |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Brain Performance and Nutrition Research Centre | Newcastle Upon Tyne | Tyne And Wear |
Lead Sponsor | Collaborator |
---|---|
Northumbria University |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Acute change in global cognitive task performance | Changes in executive function, working memory, spatial memory, secondary memory and attention as compared to pre-treatment performance on day 1. All tasks have the same x3 outcome measures; accuracy (% correct), errors (% incorrect) and speed (milliseconds) and the individual task scores will therefore be collapsed into global cognitive domains. | 120 minutes and 240 minutes post dose on day 1 of treatment supplementation | |
Primary | Acute changes in mood; as assessed by the Bond-Lader mood scales | The Bond-Lader mood visual analogue scales will be used at baseline and 120- and 240-minutes post dose on day 1. The derived scores on alertness, calmness and contentedness will be 'changed-from-baseline' and this score compared across the treatments. | 120 minutes and 240 minutes post dose on day 1 of treatment supplementation | |
Primary | Interim changes in global cognitive task performance | Changes in attention, executive function, working memory and episodic memory as compared to pre-treatment performance on day 1. All tasks have the same x3 outcome measures; accuracy (% correct), errors (% incorrect) and speed (milliseconds) and the individual task scores will therefore be collapsed into global cognitive domains. | Day 7, day 14, day 21 and day 28 | |
Primary | Chronic changes in cognitive task performance | Changes in executive function, working memory, spatial memory, secondary memory and attention as compared to pre-treatment performance on day 1. All tasks have the same x3 outcome measures; accuracy (% correct), errors (% incorrect) and speed (milliseconds) and the individual task scores will therefore be collapsed into global cognitive domains. | Pre-dose, 120 minutes and 240 minutes post-dose on day 29 of treatment supplementation | |
Primary | Chronic changes in mood; as assessed by the Bond-Lader mood scales | The Bond-Lader mood visual analogue scales will be used at baseline and 120- and 240-minutes post dose on day 29. The derived scores on alertness, calmness and contentedness will be 'changed-from-baseline' and this score compared across the treatments. | Pre-dose, 120 minutes and 240 minutes post dose on day 29 of treatment supplementation | |
Primary | Change in prospective memory performance; as assessed by a prospective memory task (the prospective remembering video task) | This individual task is called the Prospective Remembering Video Task (PRVP) and requires participants to remember a list of remembered locations and actions and identify these as they watch a video with them unfolding. The task is scored for difference in prospective memory/location learning performance between active and placebo on day 25 of supplementation period and also the difference in amount of memory decay of prospective memory/location learning on day 29 of treatment supplementation. | Day 25 and day 29 | |
Primary | Acute changes in mood; as assessed by the 'state, trait anxiety inventory' (STAI) | The STAI will be used at baseline and 120- and 240-minutes post dose on day 1. The anxiety scores will be 'changed-from-baseline' and this score compared across the treatments. | 120 minutes and 240 minutes post dose on day 29 of treatment supplementation | |
Primary | Chronic changes in mood; as assessed by the 'state, trait anxiety inventory' (STAI) | The STAI will be used at baseline and 120- and 240-minutes post dose on day 29. The anxiety scores will be 'changed-from-baseline' and this score compared across the treatments. | 120 minutes and 240 minutes post dose on day 29 of treatment supplementation | |
Secondary | Acute changes in blood pressure | Changes in blood pressure (BP) as compared to pre-dose BP on day 1. BP is assessed via forearm cuff and provides systolic and diastolic BP. | 120 minutes and 240 minutes post dose on day 1 of treatment supplementation | |
Secondary | Chronic changes in blood pressure | Changes in blood pressure (BP) as compared to pre-dose BP on day 1. BP is assessed via forearm cuff and provides systolic and diastolic BP. | Pre-dose, 120 minutes and 240 minutes post dose on day 29 of treatment supplementation | |
Secondary | Acute changes in heart rate | Changes in heart rate (HR) as compared to pre-dose HR on day 1. HR is assessed via forearm cuff. | 120 minutes and 240 minutes post dose on day 1 of treatment supplementation | |
Secondary | Chronic changes in heart rate | Changes in heart rate (HR) as compared to pre-dose HR on day 1. HR is assessed via forearm cuff. | Pre-dose, 120 minutes and 240 minutes post dose on day 29 of treatment supplementation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05712005 -
Cognitive Testing in Diverse Populations to Further the Objective and Clinical Understanding of Cognivue Study
|
||
Completed |
NCT05343208 -
Effectiveness of Online Therapy to Prevent Burnout
|
N/A | |
Active, not recruiting |
NCT05143294 -
Conectar Jugando: Board Games in Elementary Classrooms (6-12 Years Old) to Improve Executive Functions
|
N/A | |
Completed |
NCT05267730 -
Conectar Jugando: Board Games in Rural Elementary Classrooms (6-12 Years Old) to Improve Executive Functions
|
N/A | |
Completed |
NCT03987477 -
Online Intervention to Modify Interpretation Biases in Depression
|
N/A | |
Completed |
NCT05075850 -
Multicenter Sub-study for LAANTERN Registry NCT02392078 That Will Include Comprehensive Neuropsychological Assessment Data Collection
|
||
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Completed |
NCT03689348 -
Acute and Chronic Effects of Avena Sativa on Cognition and Stress
|
N/A | |
Completed |
NCT03674281 -
The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System
|
N/A | |
Active, not recruiting |
NCT05229705 -
Exercise in Older Adults at Risk for Type 2 Diabetes
|
N/A | |
Suspended |
NCT05001789 -
Cognitive Functioning in Opioid Use Disorder
|
N/A | |
Terminated |
NCT03337282 -
Incidence and Characteristics of Postoperative Cognitive Dysfunction in Elderly Quebec Francophone Patients
|
||
Recruiting |
NCT05014399 -
Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
|
||
Completed |
NCT03657537 -
Effects of Ketone Bodies on Cognition in Type 2 Diabetes
|
Phase 1 | |
Completed |
NCT05543811 -
The Influence of Food for Special Dietary Use - Spread Enriched With 5-hydroxytryptophan, Theanine and Gamma-aminobutyric Acid on Psychophysiological Functions of Subjects Without Meaningful Organic and Cognitive Pathology
|
N/A | |
Recruiting |
NCT05699226 -
Amplitude Titration to Improve ECT Clinical Outcomes
|
N/A | |
Recruiting |
NCT05026541 -
Resilience to Sleep Deprivation and Changes in Sleep Architecture in Shoonya Meditators
|
N/A | |
Active, not recruiting |
NCT03255499 -
Efficacy of the MovinCog Intervention in Children
|
N/A | |
Not yet recruiting |
NCT06252376 -
Effects of Blood Pressure on Cognition and Cerebral Hemodynamics in PD
|
N/A | |
Recruiting |
NCT06099405 -
Yoga Training and Retinal Vasculature
|
N/A |